Avonex, Interferon Beta-1a Wire
Comprehensive News Feed for Avonex, Interferon Beta-1a (generic).
Results 1 - 20 of 38 in Avonex, Interferon Beta-1a (generic)
-
Whatever Tysabri Outcome, Biogen Idec Should Survive
Biogen Idec 's key multiple sclerosis drug is in the news again, as the European Medicines Agency has started a safety review of Tysabri , citing more confirmed cases of a rare - but potentially fatal - viral infection of the brain, called progressive multifocal leukoencephalopathy , previously linked to the drug. Comment?
-
EMD Serono, Inc. Named as a Top Employer by Science Magazine
EMD Serono, Inc., an affiliate of Merck KGaA, Darmstadt, Germany, announced today that Science magazine has named it one of the world's leading biotechnology and pharmaceutical employers. Comment?
-
Compelling new data on Novartis' oral MS therapy
Two-year Phase III study shows Novartis oral MS therapy FTY720 significantly reduces relapses and disability progression * FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] * Results build on Phase III TRANSFORMS one-year study showing FTY720 reduced relapses significantly more ... Comment?
-
Oral Pill Fingolimod Reduces Relapses And Disability Progression
Drug manufacturer Novartis has announced further results from its phase III study of the oral pill fingolimod in people with relapsing remitting multiple sclerosis . Comment?
-
Clinical trial results conclude Novartis' MS drug yields 'significant' results
BASEL,A Switzerland Patients taking an investigational drug for multiple sclerosis experienced a oesignificanta reductions in relapses and disability progression, according to results of a late-stage clinical trial released Wednesday. Comment?
-
Two-year Phase III study shows Novartis oral MS therapy FTY720...
The issuer is solely responsible for the content of this announcement. -------------- * FREEDOMS study shows FTY720 reduced relapse rates by 54-60% compared to placebo, and disability progression by 30-32%[1] * Results build on Phase III TRANSFORMS one-year study showing FTY720 ... Comment?
-
Results From Improve Study Show MRI Benefits of Rebif(R) Seen Early...
Data Presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis Held in Dusseldorf, Germany, From September 9-12, 2009. Comment?
-
AVONEX results in few injection site reactions, according to a clinical study
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon- , Copaxone- or Rebif - . The study also showed AVONEX patients were less likely to have missed a dose due to an ... Comment?
-
Phase 2 MS clinical trial data continues to show durable reductions in relapse rate
Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. Comment?
-
Fewer Injection Site Reactions In Patients Using AVONEX Versus...
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on Betaferon , Copaxone or Rebif . Comment?
-
Patients using Avonex have few site reactions
Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on BetaferonA , CopaxoneA or Rebif A . The study also showed AVONEX patients were less likely to have missed a dose due to an ... Comment?
-
Genzyme announces results from Phase II of alemtuzumab in multiple sclerosis
The CAMMS223 Phase II trial compared alemtuzumab to an approved MS therapy Rebif in early, relapsing-remitting multiple sclerosis patients who had received no prior therapy. Comment?
-
Genzyme's Alemtuzumab for Multiple Sclerosis Shows Durable Treatment...
Sep 11, 2009 - Genzyme Corporation reported today that four-year follow-up data from its completed Phase 2 multiple sclerosis trial continued to show durable reductions in relapse rate and sustained accumulation of disability three years after the majority of patients received their last course of the investigational compound alemtuzumab. Comment?
-
Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in...
Results from IMPROVE Study Show MRI Benefits of Rebif Seen Early in Relapsing-Remitting Multiple Sclerosis Treatment and Sustained Over Time Data presented at the 25th Congress of the European Committee for the Treatment and Research in Multiple Sclerosis held in Duesseldorf, Germany, from September 9-12, 2009. Comment?
-
16:41]( ... )- ' ' s Y - Y - BW- Fewer Injection Site...
I'I I'IsIYI I I I I- I I I IYI - BW- Fewer Injection Site Reactions in Patients Using AVONEXA Versus Sub... Fewer Injection Site Reactions in Patients Using AVONEXA Versus Sub-cutaneous Interferon and Glatiramer Acetate for the Treatment of Multiple Sclerosis CAMBRIDGE, Mass.-- -- Data from an observational phase IV study of 499 patients ... Comment?
-
Fewer injection site reactions in patients using Avonex
Sept. 11, 2009 -- Data from an observational phase IV study of 499 patients entitled The Swiss MS Skin Project show that multiple sclerosis patients taking AVONEX reported significantly fewer injection site reactions compared to patients on BetaferonA , CopaxoneA or Rebif A . The study also showed AVONEX patients were less likely to have missed a ... Comment?
-
Biogen Idec Showcases More Than 70 Data Presentations at the 25th...
Sep 2, 2009 - Biogen Idec today announced more than 70 platform and poster presentations from the company's multiple sclerosis franchise being presented during the 25th Congress of the European Committee for Treatment and Research in Multiple Sclerosis in Dsseldorf, Germany. Comment?
-
BioMS, Lilly Scratch Heads Over Dirucotide Phase III MS Blowup
Shares of small Canadian biotech BioMS Medical Corp. took a beating after its only drug candidate, dirucotide, failed to delay disease progression over placebo in a Phase III trial in secondary progressive multiple sclerosis patients. Comment?
-
Merck KGaA Submits Application For Cladribine Tablets As Multiple Sclerosis Therapy In Europe
Main Category: Multiple Sclerosis Also Included In: Regulatory Affairs / Drug Approvals ; Clinical Trials / Drug Trials Article Date: 25 Jul 2009 - 1:00 PDT Merck KGaA announced the submission of a marketing authorization application to the European Medicines Agency for Cladribine Tablets, Merck's proprietary investigational oral formulation of ... Comment?
-
NIH Deepens Investment In Combination Study Of MS Drugs
The first large-scale "CombiRX" clinical trial testing the combined use of FDA-approved interferon beta-1a and glatiramer acetate to treat relapsing-remitting MS has just received a $19-million renewal grant from the National Institutes of Health. Comment?
Avonex, Interferon Beta-1a Forum
Most Popular
- Arkansas 10-Year-Old Won't Pledge Allegiance Until Gays Gain Equality. - 814 comments
- Obama's Muslim Problem - Has he been too conciliatory? - 183 comments
- Napolitano pronounces US border more secure now - 129 comments
- Catholic Church gives D.C. ultimatum on same-sex marriage issue - 348 comments
- Churches targeted by 'gay' intimidation campaign - 152 comments
- Ex-congressman gets 13 years in freezer cash case - 86 comments
- KSP arrests two Washington Co., KY deputies - 80 comments
- Obama urges Congress to put off Fort Hood probe - 107 comments
- Alabama legislator seeks to block same-sex benefits - 86 comments
- France accuses Israel of not wanting peace - 81 comments
|
Reach local customers. Engage a specific demographic. Maximize business-to-business opportunities. Topix can deliver your message.
|
Copyright ©2009 Topix LLC
